Total Payments
$66,781
2024 Payments
$2,473
Companies
46
Transactions
1,156
Medicare Patients
10,250
Medicare Billing
$9.1M
Payment Breakdown by Category
Research$46,259 (69.3%)
Food & Beverage$20,484 (30.7%)
Education$37.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $46,259 | 55 | 69.3% |
| Food and Beverage | $20,484 | 1,095 | 30.7% |
| Education | $37.39 | 6 | 0.1% |
Payments by Type
Research
$46,259
55 transactions
General
$20,522
1,101 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim International GmbH | $22,656 | 42 | $0 (2017) |
| Eli Lilly and Company | $12,211 | 8 | $0 (2024) |
| Celgene Corporation | $11,736 | 35 | $0 (2019) |
| Amgen Inc. | $3,770 | 172 | $0 (2024) |
| ABBVIE INC. | $2,655 | 155 | $0 (2024) |
| UCB, Inc. | $1,730 | 87 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,579 | 83 | $0 (2024) |
| Janssen Biotech, Inc. | $1,559 | 75 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,035 | 55 | $0 (2024) |
| Horizon Therapeutics plc | $977.16 | 44 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,473 | 98 | Amgen Inc. ($648.67) |
| 2023 | $2,663 | 125 | Amgen Inc. ($1,027) |
| 2022 | $1,958 | 92 | Horizon Therapeutics plc ($428.75) |
| 2021 | $2,384 | 141 | Amgen Inc. ($414.41) |
| 2020 | $2,395 | 127 | Amgen Inc. ($543.73) |
| 2019 | $2,747 | 156 | AbbVie, Inc. ($463.07) |
| 2018 | $18,332 | 188 | Eli Lilly and Company ($11,807) |
| 2017 | $33,829 | 229 | Boehringer Ingelheim International GmbH ($22,656) |
All Payment Transactions
1,156 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | DePuy Synthes Sales Inc. | ORTHOVISC (Device), MONOVISC, PEAK | Food and Beverage | In-kind items and services | $33.45 | General |
| Category: Sports Early Intervention | ||||||
| 12/18/2024 | Fresenius Kabi USA, LLC | — | Food and Beverage | In-kind items and services | $16.09 | General |
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Immunology | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $2.80 | General |
| Category: Immunology | ||||||
| 12/02/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Fresenius Kabi USA, LLC | — | Food and Beverage | In-kind items and services | $15.73 | General |
| 11/20/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: Inflammation | ||||||
| 11/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $113.26 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | SOBI, INC | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $4.22 | General |
| Category: Inflammation | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Immunology | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $3.07 | General |
| Category: Immunology | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $2.85 | General |
| Category: Immunology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $32.22 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $17.40 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Biosimilars | ||||||
| 10/21/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: Inflammation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Multiple dose in RA | Boehringer Ingelheim International GmbH | $8,024 | 6 |
| BI 695501 self administ. auto-injector | Boehringer Ingelheim International GmbH | $7,151 | 34 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $5,533 | 1 |
| Anti-CD20 in rheumatoid arthritis | Boehringer Ingelheim International GmbH | $4,569 | 1 |
| CC-10004-PSA-005 | Celgene Corporation | $4,042 | 1 |
| CC-10004-AS-001 | Celgene Corporation | $3,636 | 2 |
| CC-10004-AS-001 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITI | Celgene Corporation | $3,631 | 1 |
| BI 695500 in RA open label extension | Boehringer Ingelheim International GmbH | $2,913 | 1 |
| A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $2,909 | 1 |
| A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $2,089 | 3 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN BDMARD-NAIVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $1,566 | 2 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $114.46 | 1 |
| A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | Gilead Sciences, Inc. | $84.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 2,980 | 187,579 | $5.9M | $2.6M |
| 2022 | 26 | 2,187 | 113,160 | $3.3M | $1.5M |
| 2021 | 25 | 2,586 | 153,431 | $5.1M | $2.6M |
| 2020 | 25 | 2,497 | 117,155 | $4.7M | $2.5M |
Total Patients
10,250
Total Services
571,325
Medicare Billing
$9.1M
Procedure Codes
100
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 56 | 28,425 | $2.0M | $956,389 | 48.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 367 | 28,620 | $787,980 | $522,037 | 66.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 41 | 9,870 | $1.1M | $259,048 | 22.8% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 28 | 60,400 | $543,600 | $235,812 | 43.4% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 12 | 37,560 | $262,920 | $175,626 | 66.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 762 | 1,161 | $233,970 | $111,064 | 47.5% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 13 | 9,350 | $327,250 | $98,435 | 30.1% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 13 | 7,980 | $143,640 | $63,082 | 43.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 87 | 434 | $141,050 | $46,185 | 32.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 175 | 538 | $67,450 | $28,176 | 41.8% |
| 77085 | Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | Office | 2023 | 326 | 326 | $29,340 | $17,584 | 59.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 443 | 1,040 | $41,600 | $11,382 | 27.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 66 | 66 | $18,815 | $7,943 | 42.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 57 | 327 | $35,970 | $7,642 | 21.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 201 | 514 | $7,164 | $4,318 | 60.3% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 26 | 109 | $10,355 | $3,369 | 32.5% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 108 | 536 | $68,072 | $3,307 | 4.9% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 23 | 27 | $7,400 | $2,531 | 34.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 20 | 22 | $3,600 | $1,205 | 33.5% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 15 | 16 | $1,700 | $701.25 | 41.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 22 | 112 | $952.00 | $489.18 | 51.4% |
| 73120 | X-ray of hand, 2 views | Office | 2023 | 12 | 22 | $2,640 | $471.08 | 17.8% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 67 | 78 | $1,950 | $413.80 | 21.2% |
| J1020 | Injection, methylprednisolone acetate, 20 mg | Office | 2023 | 40 | 46 | $690.00 | $174.62 | 25.3% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 37 | 16,825 | $1.2M | $582,538 | 49.5% |
About Dr. Steven Klein, MD
Dr. Steven Klein, MD is a Rheumatology healthcare provider based in Hagerstown, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1730185471.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Klein, MD has received a total of $66,781 in payments from pharmaceutical and medical device companies, with $2,473 received in 2024. These payments were reported across 1,156 transactions from 46 companies. The most common payment nature is "" ($46,259).
As a Medicare-enrolled provider, Klein has provided services to 10,250 Medicare beneficiaries, totaling 571,325 services with total Medicare billing of $9.1M. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Hagerstown, MD
- Active Since 06/27/2005
- Last Updated 03/13/2017
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1730185471
Products in Payments
- Otezla (Drug) $11,521
- TALTZ (Drug) $9,701
- Enbrel (Biological) $2,249
- Cimzia (Drug) $1,629
- COSENTYX (Biological) $1,492
- RINVOQ (Biological) $1,023
- KRYSTEXXA (Biological) $1,010
- ORENCIA (Biological) $912.51
- ACTHAR (Biological) $911.96
- SIMPONI ARIA (Biological) $872.34
- BENLYSTA (Biological) $865.84
- SAPHNELO (Biological) $858.59
- Humira (Biological) $681.66
- EVENITY (Biological) $591.99
- KRYSTEXXA (Drug) $563.90
- Rituxan (Biological) $543.01
- TREMFYA (Drug) $420.47
- Prolia (Biological) $377.24
- AVSOLA (Biological) $329.52
- XELJANZ (Drug) $324.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.